Get started
Work

A Prospective Phase 2 Clinical Trial of KIR Mismatched Unrelated Donor Transplantation for Children and Young Adults with High Risk AML: A Report of Children's Oncology Group AAML05P1 Study

Year: 2017
Type: article
Study design: Clinical Trial
Abstract: Background: Young people with high risk AML have a poor prognosis. AML patients receiving killer immunoglobulin-like receptor (KIR) mismatched haploidentical HSCT have reported improved survival due to reduced TRM and relapse. COG AAML05P1 is a prospective phase 2 trial of unrelated donor HSCT in which KIR typing of donors was available to the treating physician at the time of donor selection. The aim of the study was to determine whether prospective selection of KIR mismatched donors is feasible and improves outcomes.
DOI: 10.1016/j.bbmt.2017.01.053
Authors: Stella M. Davies, Robert Iannone, Todd Alonzo, Jim Wang, Robert Gerbing, Sandeep Soni, E. Anders Kolb, Soheil Meshinchi, Paul Orchard, Linda J. Burns, Shalini Shenoy, Wing H. Leung
Institutions: Cincinnati Children's Hospital Medical Center, AstraZeneca (United States), University of Southern California, Children's Oncology Group, Bluebird Bio (United States), Alfred I. duPont Hospital for Children, Seattle Children's Hospital, Fred Hutch Cancer Center, University of Minnesota, Masonic Cancer Center, National Marrow Donor Program, St. Louis Children's Hospital, Washington University in St. Louis, St. Jude Children's Research Hospital
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2589328826
FWCI:
Cites:
Cited by:
Related to: 10